Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Thumbnail

SNMMI: PET/CT + breast MR predict chemo’s ability to prolong life for breast cancer patients

The combination of PET and MR imaging data can provide physicians with information on the effectiveness of chemotherapy prior to surgery, according to research presented at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver.

CMS halts coverage with evidence development for PET

The Centers for Medicare & Medicaid Services on June 11 issued a ruling to end the requirement for coverage with evidence development for scans using 18F-FDG PET under the National Oncologic Pet Registry (NOPR) for 18-F FDG PET exams.

SNMMI: Amino acid PET helps shed light on pediatric glioma

Use of O-(2-[18F]-fluoroethyl)-L-tyrosine (F-18 FET), an amino acid PET agent, was shown to be highly accurate in identifying brain lesions in children suspected of glioma cerebral cancer, according to a study presented at the Society of Nuclear Medicine and Molecular Imaging’s 2013 annual meeting in Vancouver.

SNMMI: Radioimmunotherapy + chemo boosts survival for lymphoma patients

Combining radioimmunotherapy (RIT) with chemotherapy can significantly improve chance of survival for patients with recurrent lymphoma compared with chemotherapy alone, according to a study presented at the Society of Nuclear Medicine and Molecular Imaging’s 2013 annual meeting in Vancouver.

MIM Software Showcases a Single Platform Viewing Solution for PET, CT, MRI, and Nuclear Medicine Exams at SNMMI 2013

MIM Software Inc., a leading global provider of medical imaging software, announced they will be showcasing a new version of MIM Encore that provides a single platform for viewing PET, CT, MRI and Nuclear Medicine exams at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2013 Annual Meeting.

SNMMI 2013 Image of the Year: Radium-223 Dichloride Response in Bone Metastases in Breast Cancer Patients

An 18F-FDG positron emission tomography/computed tomography (PET/CT) scan illustrating the effectiveness of radium-223 dichloride in treating bone metastases in breast cancer patients with bone-dominant disease has been selected as the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2013 Image of the Year. Researchers selected this image from more than 2,000 studies presented over the course of four days during SNMMI’s 2013 Annual Meeting in Vancouver, British Columbia, Canada.

SNMMI 2013 Image of the Year: Radium-223 Dichloride Response in Bone Metastases in Breast Cancer Patients

Vancouver, British Columbia – An 18F-FDG positron emission tomography/computed tomography (PET/CT) scan illustrating the effectiveness of radium-223 dichloride in treating bone metastases in breast cancer patients with bone-dominant disease has been selected as the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2013 Image of the Year. Researchers selected this image from more than 2,000 studies presented over the course of four days during SNMMI’s 2013 Annual Meeting in Vancouver, British Columbia, Canada.

Sequester bites NIH funding, Alzheimer’s research

With increasing prevalence of Alzheimer’s disease threatening to bankrupt Medicare and Medicaid by 2050, the fiscal pinch of the sequester could extend decades into the future and compromise already-limited progress on Alzheimer’s disease prevention and treatment. A letter in the New York Times detailed the data.